CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,875,456 | +37.9% | 1,505,976 | +100.8% | 0.08% | +44.2% |
| Q2 2023 | $23,842,500 | +145.3% | 750,000 | +88.2% | 0.05% | +136.4% |
| Q1 2023 | $9,719,903 | -22.7% | 398,520 | 0.0% | 0.02% | -26.7% |
| Q4 2022 | $12,569,321 | +11.6% | 398,520 | 0.0% | 0.03% | +7.1% |
| Q3 2022 | $11,262,000 | +33.1% | 398,520 | +24.5% | 0.03% | +47.4% |
| Q2 2022 | $8,461,000 | -39.6% | 320,000 | -20.0% | 0.02% | -29.6% |
| Q1 2022 | $14,004,000 | +39.3% | 400,000 | +29.0% | 0.03% | +50.0% |
| Q4 2021 | $10,050,000 | +36.3% | 310,000 | +24.0% | 0.02% | +20.0% |
| Q3 2021 | $7,375,000 | -42.4% | 250,000 | -50.0% | 0.02% | -40.0% |
| Q2 2021 | $12,810,000 | +55.5% | 500,000 | -16.7% | 0.02% | +47.1% |
| Q1 2021 | $8,238,000 | -17.2% | 600,000 | 0.0% | 0.02% | -22.7% |
| Q4 2020 | $9,948,000 | – | 600,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |